Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jerod Rasmussen is active.

Publication


Featured researches published by Jerod Rasmussen.


Nature Genetics | 2012

Identification of common variants associated with human hippocampal and intracranial volumes

Jason L. Stein; Sarah E. Medland; A A Vasquez; Derrek P. Hibar; R. E. Senstad; Anderson M. Winkler; Roberto Toro; K Appel; R. Bartecek; Ørjan Bergmann; Manon Bernard; Andrew Anand Brown; Dara M. Cannon; M. Mallar Chakravarty; Andrea Christoforou; M. Domin; Oliver Grimm; Marisa Hollinshead; Avram J. Holmes; Georg Homuth; J.J. Hottenga; Camilla Langan; Lorna M. Lopez; Narelle K. Hansell; Kristy Hwang; Sungeun Kim; Gonzalo Laje; Phil H. Lee; Xinmin Liu; Eva Loth

Identifying genetic variants influencing human brain structures may reveal new biological mechanisms underlying cognition and neuropsychiatric illness. The volume of the hippocampus is a biomarker of incipient Alzheimers disease and is reduced in schizophrenia, major depression and mesial temporal lobe epilepsy. Whereas many brain imaging phenotypes are highly heritable, identifying and replicating genetic influences has been difficult, as small effects and the high costs of magnetic resonance imaging (MRI) have led to underpowered studies. Here we report genome-wide association meta-analyses and replication for mean bilateral hippocampal, total brain and intracranial volumes from a large multinational consortium. The intergenic variant rs7294919 was associated with hippocampal volume (12q24.22; N = 21,151; P = 6.70 × 10−16) and the expression levels of the positional candidate gene TESC in brain tissue. Additionally, rs10784502, located within HMGA2, was associated with intracranial volume (12q14.3; N = 15,782; P = 1.12 × 10−12). We also identified a suggestive association with total brain volume at rs10494373 within DDR2 (1q23.3; N = 6,500; P = 5.81 × 10−7).


Molecular Psychiatry | 2016

Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium

T G M van Erp; Derrek P. Hibar; Jerod Rasmussen; David C. Glahn; Godfrey D. Pearlson; Ole A. Andreassen; Ingrid Agartz; Lars T. Westlye; Unn K. Haukvik; Anders M. Dale; Ingrid Melle; Cecilie B. Hartberg; Oliver Gruber; Bernd Kraemer; David Zilles; Gary Donohoe; Sinead Kelly; Colm McDonald; Derek W. Morris; Dara M. Cannon; Aiden Corvin; Marise W J Machielsen; Laura Koenders; L. de Haan; Dick J. Veltman; Theodore D. Satterthwaite; Daniel H. Wolf; R.C. Gur; Raquel E. Gur; Steve Potkin

The profile of brain structural abnormalities in schizophrenia is still not fully understood, despite decades of research using brain scans. To validate a prospective meta-analysis approach to analyzing multicenter neuroimaging data, we analyzed brain MRI scans from 2028 schizophrenia patients and 2540 healthy controls, assessed with standardized methods at 15 centers worldwide. We identified subcortical brain volumes that differentiated patients from controls, and ranked them according to their effect sizes. Compared with healthy controls, patients with schizophrenia had smaller hippocampus (Cohen’s d=−0.46), amygdala (d=−0.31), thalamus (d=−0.31), accumbens (d=−0.25) and intracranial volumes (d=−0.12), as well as larger pallidum (d=0.21) and lateral ventricle volumes (d=0.37). Putamen and pallidum volume augmentations were positively associated with duration of illness and hippocampal deficits scaled with the proportion of unmedicated patients. Worldwide cooperative analyses of brain imaging data support a profile of subcortical abnormalities in schizophrenia, which is consistent with that based on traditional meta-analytic approaches. This first ENIGMA Schizophrenia Working Group study validates that collaborative data analyses can readily be used across brain phenotypes and disorders and encourages analysis and data sharing efforts to further our understanding of severe mental illness.


Journal of Magnetic Resonance Imaging | 2012

Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies.

Gary H. Glover; Bryon A. Mueller; Jessica A. Turner; Theo G.M. van Erp; Thomas T. Liu; Douglas N. Greve; James T. Voyvodic; Jerod Rasmussen; Gregory G. Brown; David B. Keator; Vince D. Calhoun; Hyo Jong Lee; Judith M. Ford; Daniel H. Mathalon; Michele T. Diaz; Daniel S. O'Leary; Syam Gadde; Adrian Preda; Kelvin O. Lim; Cynthia G. Wible; Hal S. Stern; Aysenil Belger; Gregory McCarthy; Steven G. Potkin

This report provides practical recommendations for the design and execution of multicenter functional MRI (MC‐fMRI) studies based on the collective experience of the Function Biomedical Informatics Research Network (FBIRN). The study was inspired by many requests from the fMRI community to FBIRN group members for advice on how to conduct MC‐fMRI studies. The introduction briefly discusses the advantages and complexities of MC‐fMRI studies. Prerequisites for MC‐fMRI studies are addressed before delving into the practical aspects of carefully and efficiently setting up a MC‐fMRI study. Practical multisite aspects include: (i) establishing and verifying scan parameters including scanner types and magnetic fields, (ii) establishing and monitoring of a scanner quality program, (iii) developing task paradigms and scan session documentation, (iv) establishing clinical and scanner training to ensure consistency over time, (v) developing means for uploading, storing, and monitoring of imaging and other data, (vi) the use of a traveling fMRI expert, and (vii) collectively analyzing imaging data and disseminating results. We conclude that when MC‐fMRI studies are organized well with careful attention to unification of hardware, software and procedural aspects, the process can be a highly effective means for accessing a desired participant demographics while accelerating scientific discovery. J. Magn. Reson. Imaging 2012;36:39–54.


Molecular Psychiatry | 2016

Subcortical volumetric abnormalities in bipolar disorder.

Derrek P. Hibar; Lars T. Westlye; T G M van Erp; Jerod Rasmussen; Cassandra D. Leonardo; Joshua Faskowitz; Unn K. Haukvik; Cecilie B. Hartberg; Nhat Trung Doan; Ingrid Agartz; Anders M. Dale; Oliver Gruber; Bernd Krämer; Sarah Trost; Benny Liberg; Christoph Abé; C J Ekman; Martin Ingvar; Mikael Landén; Scott C. Fears; Nelson B. Freimer; Carrie E. Bearden; Emma Sprooten; David C. Glahn; Godfrey D. Pearlson; Louise Emsell; Joanne Kenney; C. Scanlon; Colm McDonald; Dara M. Cannon

Considerable uncertainty exists about the defining brain changes associated with bipolar disorder (BD). Understanding and quantifying the sources of uncertainty can help generate novel clinical hypotheses about etiology and assist in the development of biomarkers for indexing disease progression and prognosis. Here we were interested in quantifying case–control differences in intracranial volume (ICV) and each of eight subcortical brain measures: nucleus accumbens, amygdala, caudate, hippocampus, globus pallidus, putamen, thalamus, lateral ventricles. In a large study of 1710 BD patients and 2594 healthy controls, we found consistent volumetric reductions in BD patients for mean hippocampus (Cohen’s d=−0.232; P=3.50 × 10−7) and thalamus (d=−0.148; P=4.27 × 10−3) and enlarged lateral ventricles (d=−0.260; P=3.93 × 10−5) in patients. No significant effect of age at illness onset was detected. Stratifying patients based on clinical subtype (BD type I or type II) revealed that BDI patients had significantly larger lateral ventricles and smaller hippocampus and amygdala than controls. However, when comparing BDI and BDII patients directly, we did not detect any significant differences in brain volume. This likely represents similar etiology between BD subtype classifications. Exploratory analyses revealed significantly larger thalamic volumes in patients taking lithium compared with patients not taking lithium. We detected no significant differences between BDII patients and controls in the largest such comparison to date. Findings in this study should be interpreted with caution and with careful consideration of the limitations inherent to meta-analyzed neuroimaging comparisons.


PLOS ONE | 2013

Brown Adipose Tissue Quantification in Human Neonates Using Water-Fat Separated MRI

Jerod Rasmussen; Sonja Entringer; Annie Nguyen; Theo G.M. van Erp; Ana Guijarro; James M. Swanson; Daniele Piomelli; Pathik D. Wadhwa; Claudia Buss; Steven G. Potkin

There is a major resurgence of interest in brown adipose tissue (BAT) biology, particularly regarding its determinants and consequences in newborns and infants. Reliable methods for non-invasive BAT measurement in human infants have yet to be demonstrated. The current study first validates methods for quantitative BAT imaging of rodents post mortem followed by BAT excision and re-imaging of excised tissues. Identical methods are then employed in a cohort of in vivo infants to establish the reliability of these measures and provide normative statistics for BAT depot volume and fat fraction. Using multi-echo water-fat MRI, fat- and water-based images of rodents and neonates were acquired and ratios of fat to the combined signal from fat and water (fat signal fraction) were calculated. Neonatal scans (n = 22) were acquired during natural sleep to quantify BAT and WAT deposits for depot volume and fat fraction. Acquisition repeatability was assessed based on multiple scans from the same neonate. Intra- and inter-rater measures of reliability in regional BAT depot volume and fat fraction quantification were determined based on multiple segmentations by two raters. Rodent BAT was characterized as having significantly higher water content than WAT in both in situ as well as ex vivo imaging assessments. Human neonate deposits indicative of bilateral BAT in spinal, supraclavicular and axillary regions were observed. Pairwise, WAT fat fraction was significantly greater than BAT fat fraction throughout the sample (ΔWAT-BAT = 38%, p<10−4). Repeated scans demonstrated a high voxelwise correlation for fat fraction (Rall = 0.99). BAT depot volume and fat fraction measurements showed high intra-rater (ICCBAT,VOL = 0.93, ICCBAT,FF = 0.93) and inter-rater reliability (ICCBAT,VOL = 0.86, ICCBAT,FF = 0.93). This study demonstrates the reliability of using multi-echo water-fat MRI in human neonates for quantification throughout the torso of BAT depot volume and fat fraction measurements.


Developmental Cognitive Neuroscience | 2016

Implications of newborn amygdala connectivity for fear and cognitive development at 6-months-of-age

Alice M. Graham; Claudia Buss; Jerod Rasmussen; Marc D. Rudolph; Damion V. Demeter; John H. Gilmore; Martin Styner; Sonja Entringer; Pathik D. Wadhwa; Damien A. Fair

The first year of life is an important period for emergence of fear in humans. While animal models have revealed developmental changes in amygdala circuitry accompanying emerging fear, human neural systems involved in early fear development remain poorly understood. To increase understanding of the neural foundations of human fear, it is important to consider parallel cognitive development, which may modulate associations between typical development of early fear and subsequent risk for fear-related psychopathology. We, therefore, examined amygdala functional connectivity with rs-fcMRI in 48 neonates (M = 3.65 weeks, SD = 1.72), and measured fear and cognitive development at 6-months-of-age. Stronger, positive neonatal amygdala connectivity to several regions, including bilateral anterior insula and ventral striatum, was prospectively associated with higher fear at 6-months. Stronger amygdala connectivity to ventral anterior cingulate/anterior medial prefrontal cortex predicted a specific phenotype of higher fear combined with more advanced cognitive development. Overall, findings demonstrate unique profiles of neonatal amygdala functional connectivity related to emerging fear and cognitive development, which may have implications for normative and pathological fear in later years. Consideration of infant fear in the context of cognitive development will likely contribute to a more nuanced understanding of fear, its neural bases, and its implications for future mental health.


Psychiatry Research-neuroimaging | 2014

A multi-scanner study of subcortical brain volume abnormalities in schizophrenia.

Theo G.M. van Erp; Douglas N. Greve; Jerod Rasmussen; Jessica A. Turner; Vince D. Calhoun; Sarah Young; Bryon A. Mueller; Gregory G. Brown; Gregory McCarthy; Gary H. Glover; Kelvin O. Lim; Juan Bustillo; Aysenil Belger; Sarah McEwen; James T. Voyvodic; Daniel H. Mathalon; David B. Keator; Adrian Preda; Dana Nguyen; Judith M. Ford; Steven G. Potkin; Fbirn

Schizophrenia patients show significant subcortical brain abnormalities. We examined these abnormalities using automated image analysis software and provide effect size estimates for prospective multi-scanner schizophrenia studies. Subcortical and intracranial volumes were obtained using FreeSurfer 5.0.0 from high-resolution structural imaging scans from 186 schizophrenia patients (mean age±S.D.=38.9±11.6, 78% males) and 176 demographically similar controls (mean age±S.D.=37.5±11.2, 72% males). Scans were acquired from seven 3-Tesla scanners. Univariate mixed model regression analyses compared between-group volume differences. Weighted mean effect sizes (and number of subjects needed for 80% power at α=0.05) were computed based on the individual single site studies as well as on the overall multi-site study. Schizophrenia patients have significantly smaller intracranial, amygdala, and hippocampus volumes and larger lateral ventricle, putamen and pallidum volumes compared with healthy volunteers. Weighted mean effect sizes based on single site studies were generally larger than effect sizes computed based on analysis of the overall multi-site sample. Prospectively collected structural imaging data can be combined across sites to increase statistical power for meaningful group comparisons. Even when using similar scan protocols at each scanner, some between-site variance remains. The multi-scanner effect sizes provided by this study should help in the design of future multi-scanner schizophrenia imaging studies.


NeuroImage | 2016

The Function Biomedical Informatics Research Network Data Repository

David B. Keator; Theo G.M. van Erp; Jessica A. Turner; Gary H. Glover; Bryon A. Mueller; Thomas T. Liu; James T. Voyvodic; Jerod Rasmussen; Vince D. Calhoun; Hyo Jong Lee; Arthur W. Toga; Sarah McEwen; Judith M. Ford; Daniel H. Mathalon; Michele T. Diaz; Daniel S. O'Leary; H. Jeremy Bockholt; Syam Gadde; Adrian Preda; Cynthia G. Wible; Hal S. Stern; Aysenil Belger; Gregory McCarthy; Steven G. Potkin

The Function Biomedical Informatics Research Network (FBIRN) developed methods and tools for conducting multi-scanner functional magnetic resonance imaging (fMRI) studies. Method and tool development were based on two major goals: 1) to assess the major sources of variation in fMRI studies conducted across scanners, including instrumentation, acquisition protocols, challenge tasks, and analysis methods, and 2) to provide a distributed network infrastructure and an associated federated database to host and query large, multi-site, fMRI and clinical data sets. In the process of achieving these goals the FBIRN test bed generated several multi-scanner brain imaging data sets to be shared with the wider scientific community via the BIRN Data Repository (BDR). The FBIRN Phase 1 data set consists of a traveling subject study of 5 healthy subjects, each scanned on 10 different 1.5 to 4 T scanners. The FBIRN Phase 2 and Phase 3 data sets consist of subjects with schizophrenia or schizoaffective disorder along with healthy comparison subjects scanned at multiple sites. In this paper, we provide concise descriptions of FBIRNs multi-scanner brain imaging data sets and details about the BIRN Data Repository instance of the Human Imaging Database (HID) used to publicly share the data.


Genomics | 2013

Increased CNV-Region deletions in mild cognitive impairment (MCI) and Alzheimer's disease (AD) subjects in the ADNI sample

Guia Guffanti; Federica Torri; Jerod Rasmussen; Andrew P. Clark; Anita Lakatos; Jessica A. Turner; James H. Fallon; Andrew J. Saykin; Michael W. Weiner; Marquis P. Vawter; James A. Knowles; Steven G. Potkin; Fabio Macciardi

We investigated the genome-wide distribution of CNVs in the Alzheimers disease (AD) Neuroimaging Initiative (ADNI) sample (146 with AD, 313 with Mild Cognitive Impairment (MCI), and 181 controls). Comparison of single CNVs between cases (MCI and AD) and controls shows overrepresentation of large heterozygous deletions in cases (p-value<0.0001). The analysis of CNV-Regions identifies 44 copy number variable loci of heterozygous deletions, with more CNV-Regions among affected than controls (p=0.005). Seven of the 44 CNV-Regions are nominally significant for association with cognitive impairment. We validated and confirmed our main findings with genome re-sequencing of selected patients and controls. The functional pathway analysis of the genes putatively affected by deletions of CNV-Regions reveals enrichment of genes implicated in axonal guidance, cell-cell adhesion, neuronal morphogenesis and differentiation. Our findings support the role of CNVs in AD, and suggest an association between large deletions and the development of cognitive impairment.


Biochimica et Biophysica Acta | 2012

Empirical derivation of the reference region for computing diagnostic sensitive 18fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample ☆ ☆☆

Jerod Rasmussen; Anita Lakatos; Theo G.M. van Erp; Frithjof Kruggel; David B. Keator; James T. Fallon; Fabio Macciardi; Steven G. Potkin

Careful selection of the reference region for non-quantitative positron emission tomography (PET) analyses is critically important for Region of Interest (ROI) data analyses. We introduce an empirical method of deriving the most suitable reference region for computing neurodegeneration sensitive (18)fluorodeoxyglucose (FDG) PET ratios based on the dataset collected by the Alzheimers Disease Neuroimaging Initiative (ADNI) study. Candidate reference regions are selected based on a heat map of the difference in coefficients of variation (COVs) of FDG ratios over time for each of the Automatic Anatomical Labeling (AAL) atlas regions normalized by all other AAL regions. Visual inspection of the heat map suggests that the portion of the cerebellum and vermis superior to the horizontal fissure is the most sensitive reference region. Analyses of FDG ratio data show increases in significance on the order of ten-fold when using the superior portion of the cerebellum as compared with the traditionally used full cerebellum. The approach to reference region selection in this paper can be generalized to other radiopharmaceuticals and radioligands as well as to other disorders where brain changes over time are hypothesized and longitudinal data is available. Based on the empirical evidence presented in this study, we demonstrate the usefulness of the COV heat map method and conclude that intensity normalization based on the superior portion of the cerebellum may be most sensitive to measuring change when performing longitudinal analyses of FDG-PET ratios as well as group comparisons in Alzheimers disease. This article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.

Collaboration


Dive into the Jerod Rasmussen's collaboration.

Top Co-Authors

Avatar

Claudia Buss

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

John H. Gilmore

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Martin Styner

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge